By Tim Dougherty
The podcast currently has 28 episodes available.
Tune in for this insightful podcast with David Weinstock,
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Our guest today is another Atlanta luminary, Dr. Marvin
It’s common for people to go into the hospital for something innocuous, get an infection, and find that the bacterium doesn’t respond to antibiotic. There are strains infecting people outside of clinical settings, as well. As there are millions of deaths caused by this each year, the alarm bells are starting to go off because we are not developing a lot of new antibiotics.
How can this trend be stopped?
Disclaimers
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an
Carter Cliff is the CEO of Papillon Therapeutics. Papillon is advancing genetic medicines for life threatening conditions including Cystinosis, Friedreich's ataxia, Danon disease, and Alzheimer's disease, and the company is currently partnered with Novartis on a phase 1/2 trial for their lead candidate in cystinosis. Carter has a multi-decade career in biotech and life sciences and is also a
Enjoy the show!
Disclaimers
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role
Today we’ve got Dr. Jonathan Arambula and Dr. Krystle Karoscik of InnovoTex, an oncology therapeutics company developing a platform of smart molecules capable of circumventing drug resistance often seen in treating ovarian cancer. They’re doing it in a safer way – hear about all this and more by listening to the show!
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an
We’re going to talk with Peter Pitts, President of Center for Medicine in the Public Interest, about the IRA, which is impacting every company in biotech. The Inflation Reduction Act, or IRA, authorizes the price negotiation for a group of medicines selected by the government and, interestingly, allows no public pronouncements after the fact, by the companies.
Disclaimers
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Today we’re excited to have Subh Roy who will share his
Disclaimer
The information contained in this website and podcast are purely
The information contained in this
Nothing contained herein may be construed as a recommendation or
Today we have four very special guests, some friends
· Eddie Lai represents the MetroAtlanta Chamber of Commerce
· Courtney Law represents a group called Biolocity, which bridges Emory and Georgia Tech
· Ryan Lawler is from Biosparks Labs, funded by Georgia Technology Ventures, supporting the life science community in Atlanta
· Suna Lumeh is from a venture capital firm called Portal Innovations
This was a great group so I hope you’ll listen to the
The information contained in this website and podcast are purely informational and not considered investment
Our guest today is Gaurav Byagathvalli, a Geoge Tech alum and the CEO of Piezo Therapeurtics, a company developing an innovative nucleic acid delivery platform for DNA and mRNA vaccines. Instead of using complicated equipment they use
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate
Our guest today is Nolan Townsend, the CEO of LEXEO Therapeutics, which focused on expanding the application of crisper gene therapies past rare diseases where they’ve generally been applied to more prevalent kinds of diseases.
What got me excited for the talk was the enthusiasm that Nolan expressed for the application of genetic therapies to more common diseases, which is where all the costs live. This could have a very broad impact on society’s healthcare systems.
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
The podcast currently has 28 episodes available.